Saimura Michiyo, Anan Keisei, Mitsuyama Shoshu, Toyoshima Satoshi, Ikejiri Koji, Ohchi Tetsufumi, Rai Yoshiaki, Oikawa Tatsuji, Kudaka Manabu, Nishimura Reiki, Kuroki Shoji, Namba Kiyoshi, Nakafusa Yuji, Tamura Kazuo
Kyushu Breast Cancer Study Group, Japan.
Gan To Kagaku Ryoho. 2012 Jul;39(7):1075-9.
We evaluated the efficacy and safety of the epirubicin plus docetaxel(ET)regimen, which is a combination of active agents given to patients with inflammatory breast cancer(IBC)as a primary therapy. Nineteen patients received ET(60, 60mg/m2) every 3 weeks for 4 courses, and appropriate surgery was offered unless disease progression occurred. Seventeen patients completed the ET regimen and 1 patient was excluded because of no diffuse erythema, leaving 18 patients evaluable for the response and safety profile of this regimen. Grade 3/4 hematological toxicities were neutropenia in 15 patients(79%), febrile neutropenia in 8 patients(42%)and anemia in 3 patients(16%). Six patients(63%)received granulocyte colony-stimulating factor for febrile neutropenia. Febrile neutropenia was observed only for 1 course in all 6 patients and progression to apparent infection was not observed. Grade 3/4 non-hematological toxicities were constipation in 3, nausea in 2, anorexia in 2, fatigue in 1, vomiting in 1, diarrhea in 1, and stomatitis in 1 patient. The ET regimen was given to 16 patients(89%)as planned. The median number of courses was 4(range: 2-4). The clinical response rate was 44%. The median time to progression was 9 months, and median overall survival was 26 months. It is concluded that the ET regimen was well tolerated and effective as a primary chemotherapy for IBC.
我们评估了表柔比星联合多西他赛（ET）方案的疗效和安全性，该方案是将活性药物联合用于炎性乳腺癌（IBC）患者的一线治疗。19例患者每3周接受一次ET（60、60mg/m²），共4个疗程，除非疾病进展，否则提供适当的手术治疗。17例患者完成了ET方案，1例因无弥漫性红斑被排除，剩余18例患者可评估该方案的反应和安全性。3/4级血液学毒性包括15例（79%）患者出现中性粒细胞减少、8例（42%）患者出现发热性中性粒细胞减少和3例（16%）患者出现贫血。6例（63%）患者因发热性中性粒细胞减少接受了粒细胞集落刺激因子治疗。所有6例患者仅在1个疗程中出现发热性中性粒细胞减少，未观察到进展为明显感染的情况。3/4级非血液学毒性包括3例便秘、2例恶心、2例厌食、1例疲劳、1例呕吐、1例腹泻和1例口腔炎。16例（89%）患者按计划接受了ET方案。疗程中位数为4（范围：2 - 4）。临床缓解率为44%。中位疾病进展时间为9个月，中位总生存期为26个月。结论是ET方案作为IBC的一线化疗耐受性良好且有效。
